(1) (a) According to the SAHPRA the matter was responded to through a letter addressed to Medi-Q dated 06 October 2022 which was subsequently acknowledged by the Company through email on the same day
(b) The matter has been resolved.
(2) This matter was resolved in April 2020 following finalisation of an appeal in terms of section 24A of the Medicines and Related Substances Act, 1965 (Act No. 103 of 1965). In August 2022, Medi-Q requested a meeting and SAHPRA responded in October 2022 advising Medi-Q that, this matter was resolved when section 24A appeal was lodged and resolved.
END.